
An Irish town makes all the world's Botox. Trump's trade deal could leave a mark
Today, in the west of Ireland, they've come close to bottling it.
Westport, a small coastal town in picturesque County Mayo, is the unlikely nerve center of the world's Botox supply. A facility operated by the Chicago-based pharmaceutical company AbbVie employs at least 1,300 local people and about 500 additional contractors – an economic backbone to a town of barely 7,000 people.
Therapeutic Botox – used for conditions that include muscle spasticity, migraines, overactive bladders, certain eye conditions and excessive sweating – brought in $3.3 billion for AbbVie last year, with sales of cosmetic Botox, often used to smooth facial wrinkles, generating $2.72 billion.
But last week, US President Donald Trump took a step toward his goal of bringing that multi-billion-dollar industry home, announcing 15% tariffs on all pharmaceutical exports from the European Union.
It's a move that some fear could devastate towns like Westport, which has been transformed by the plant, from its opening by Allergan in 1977 to its acquisition and expansion in 2020 by AbbVie.
Inside the sprawling 61-acre campus – a sleek industrial presence nestled below Croagh Patrick, one of the country's most storied pilgrimage sites – vials of Botox are processed and packaged in powder form, before export to some 70 countries, according to industry estimates.
The US tops the list, accounting for 70% of total turnover at the Westport plant, which also makes eyecare products, according to the company's 2023 filings.
Uncertainty about how the tariffs will impact the company has created anxiety for some in Westport, a community where the long-term benefits of the plant's presence cannot be overstated. It's embedded in the community, powering everything from infrastructure to sports teams and local charities.
At AbbVie United Park, the home ground for the Westport United soccer club, where many of the company's workers and their families gather to train or cheer from the sidelines, locals said the tariffs could have a significant impact.
No employee of AbbVie would speak on the record with CNN. But daycare center owner Anne-Marie, who chose not to give her surname for privacy reasons, said she had heard many parents who work at the plant – and leave their children in her care – voice anxiety about what could lie ahead.
'They are worried about their jobs, they just don't know how it's going to go. Is it going to affect them? Are they going to have a job this time next year? Is the company going to be able to keep going?' she said.
'And it'll have a knock-on effect for me, you know,' she said, adding: 'If they don't have a job, I won't have a job.'
Brian Cusack, from the soccer club's development committee, was generally more upbeat about the future but believes 'a lot of change is going to happen, and maybe not change for the good.'
'Westport doesn't know what it's like without an American pharmaceutical treatment place. And I don't think we'd like to find out what it looks like without it,' said Cusack, whose 25-year-old daughter also works at the plant.
Last month, after weeks of uncertainty, the US-EU trade deal was finally agreed upon. While some in Ireland and the wider bloc welcomed the agreement, other European leaders considered it an exercise in damage limitation. The calm after its announcement was to be short-lived.
Singling out Ireland – the world's third-largest pharma exporter and home to pharma giants Johnson & Johnson and Pfizer – Trump said last Tuesday that upcoming tariffs on imported pharmaceuticals could reach 250% over the next 18 months. The threat comes as the US is currently conducting a Section 232 investigation into whether foreign drugs threaten national security, a process whose outcome could override the current US-EU trade deal.
'We want pharmaceuticals made in our country,' he said.
But tariffs alone aren't likely to spark a mass move. While the idea of bringing pharmaceutical manufacturing back to the US resonates with Trump's base, putting it into practice is fraught with challenges.
Experts say that while some drug production may shift to existing US facilities, full-scale reshoring is unlikely due to high costs, regulatory hurdles, supply chain challenges, and the long timelines for building or relocating high-tech plants – delays that could outlast any political changes.
Anne-Marie suggested that the US president's moves could be purely political but said they have still managed to sow widespread concern.
Still, she pointed to the resilience of the town – and Ireland – expressing the belief that Westport's industry will be able to outlast his administration.
'When he goes out of power, it's just gonna all change again – like it did the last time,' she said, referring to Trump's first term in office and noting that people's lives can't be dictated by what she characterized as the whims of one man.
It's an attitude that is felt around the town.
As traffic buzzed through the area, Mayo councillor Peter Flynn told CNN that while the tariffs have created 'a real headache,' people there are 'getting on with their lives.'
Flynn, who worked at Allergan for nearly three decades, said that Trump's push to quickly bring manufacturing to the US was unrealistic.
'This kind of 'lift and shift' approach that Donald Trump is talking about – it's nonsensical,' he said. He argues that moving operations is extremely difficult, even domestically—let alone overseas—because of the gross logistical challenges it brings, let alone the skilled workers it requires, many of whom he says are now leaving the US 'at speed.'
Plus, he added, 'anyone that's considering a location to move to – be it India or some of these other locations where a lot of graduates come from – are now taking the US off their map.'
AbbVie, which declined to speak with CNN for this story, has not signaled any plans to move its Botox production hub.
Addressing the tariffs in a recent public earnings call, AbbVie president Robert A. Michael said that the company was 'having constructive discussions with the administration on sectoral tariffs,' and noted that it will 'obviously continue to invest in the US.' On Tuesday, the company announced a $195 million investment in its Chicago manufacturing plant, in what it said was part of a broader commitment to invest more than $10 billion in US projects over the next decade.
Other major drugmakers have also announced that they'll be scaling up American investment in response to the new tariffs.
What these investments might mean for Ireland is unclear.
But it's possibly not great news. Last year, pharmaceuticals made up €44 billion ($51.2 billion) of Ireland's total €72.6 billion ($84.5 billion) of exports to the US.
Ahead of the tariff deal, Ireland appeared to proactively fast-track exports: €20 billion ($23 billion) worth of pharma goods were shipped to the US in the first two months of this year, according to official trade data.
And while a trade war appears to have been averted for now, American consumers could be at the receiving end of soaring drug costs.
ING analyst Diederik Stadig told CNN that a 15% tariff could increase US drug prices by 7% to 10%, adding up to $13 billion annually to health care costs. Consumers could shoulder the burden over time through higher health insurance premiums and increased drug prices at pharmacies.
For products like cosmetic Botox, which isn't covered by US health insurance, the costs of procedures already considered a luxury could also rise, analysts say, putting a further strain on wallets.
That's of concern to Westport hotelier Michael Lennon, whose US clientele are key to the tourism industry.
Driving to pick up his American guests, who were horse riding at a nearby beach on Clew Bay, where he runs an equestrian trekking outfit, Lennon said he wasn't so worried about the Westport plant taking a hit.
'There's innovative thinking in every one of our businesses… and I think we'll adapt,' Lennon said, as his jeep rattled along the Wild Atlantic Way, a scenic route along the country's rugged coast.
'My worry would be that it (the increase in tariffs) could upset the American economy, and we need all these Americans coming to Ireland.'
He then recalled a conversation he had with a Trump-supporting guest, who told him: 'What's good for America is good for Ireland.'
Lennon said he hopes that's true.
'But I don't know. And neither does she,' he said.
CNN's Tami Luhby contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
an hour ago
- Politico
How thyroid drugs became a MAHA flashpoint
Driving the Day THYROID DRUG PUSHBACK — A recent FDA letter to makers and distributors of a decades-old thyroid medication has stoked outrage among a subset of pharmacists and wellness influencers linked to the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr. The products in question are known as desiccated thyroid extracts, which are 'the dried, ground-up thyroid glands of pigs,' according to Tenille Davis, the Alliance for Pharmacy Compounding's chief advocacy officer. The animal-derived drugs, which predate the FDA as an institution, are among the treatment options for people with an underactive thyroid, or hypothyroidism, though the agency says most patients take FDA-approved synthetic hormone replacements. But last week, the FDA informed firms that market animal-derived versions that it would take action if they continued to sell them. The agency said it received more than 500 adverse event reports from the products between 1968 and February 2025 — with a substantial increase seen between 2019 and 2020. 'FDA is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. In the mean time, we will ensure access for all Americans,' FDA Commissioner Marty Makary posted on social media platform X on Thursday. The agency said it would give 'adequate time' for providers to transition patients to FDA-approved options, noting it expects them to need about 12 months. The uproar: Some wellness influencers with ties to Kennedy panned the FDA's move on social media and urged their followers to sign online petitions urging the agency to back down. Brigham Buhler, who owns the compounding pharmacy ReviveRX and is aligned with many of Kennedy's policy priorities, suggested the agency's position favors AbbVie, which makes synthetic thyroid medicines and has another candidate in clinical trials. 'Is this an example of fda working for Pharma again to create another monopoly over a drug that has been used for 100 plus years so that they can raise the prices like Pharma bro Martin [Shkreli] again?' he said in a text message. AbbVie said it would work with the agency to ensure access is not interrupted. The FDA did not respond to an interview request. 'With our ongoing clinical trials, we remain committed to these patients and their providers,' AbbVie posted Thursday on X. Why it matters: The drugs are used to prevent side effects of hypothyroidism, such as fatigue and weight gain. A doctor must closely monitor dosing because the margin between a low dose that might not be effective and a high dose that could cause side effects is small. Davis said some patients don't respond well to the synthetic drugs. While their blood panels might suggest the medication works, she said, patients continue to 'feel really crappy' until they switch to the animal-derived versions. Those people might be in the minority, Davis said, but they're still a sizeable population given the number of Americans with hypothyroidism. 'It's happened enough times where these patients aren't crazy,' she said. IT'S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. The FDA cautioned against sunscreens that come in mousse form this week, saying they might not be effective. Send tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). AROUND THE AGENCIES VAX SAFETY GROUP IS BACK — HHS said Thursday it's bringing back a 1990s-era task force on safer childhood vaccines, fulfilling a demand made by the secretary's old colleagues at an anti-vaccine group, Lauren reports. The department is reinstating the group, which was created by the 1986 law establishing a compensation program for vaccine-injured people, 'to improve the safety, quality, and oversight of vaccines administered to American children,' HHS said in a statement. NIH Director Jay Bhattacharya will lead the effort, with leaders from the FDA and the CDC participating. An HHS spokesperson didn't specify who else from the agencies would sit on the panel. HHS Secretary Robert F. Kennedy Jr. has long questioned the safety of the modern childhood vaccination schedule, suggesting the number of shots young kids receive may contribute to myriad chronic conditions, including autism. Dozens of scientific studies have found no link between vaccines and autism. Background: The Task Force on Safer Childhood Vaccines' earlier iteration disbanded in 1998 after issuing recommendations for ways the government could support the development of safer vaccines, improve adverse event surveillance and educate the public about their benefits and risks. But the law that established the task force also directed HHS to report to Congress every two years about actions it had taken to promote safer products — a paperwork burden that the Kennedy-founded group Children's Health Defense says was never met. HHS's announcement came the day before the federal government is due to respond to CHD's May lawsuit regarding Kennedy's failure to reestablish the task force. In a deadline extension request filed last month and approved, Justice Department lawyers indicated the parties could reach a settlement. 'It took nearly 30 years for HHS to do this, but at last, we have an HHS secretary who is following the law on this vital issue,' CHD President and CEO Mary Holland said in a statement. What's next: The task force is supposed to collaborate with the Advisory Commission on Childhood Vaccines, a lesser-known federal advisory committee in the vaccine space, in developing its recommendations. The secretary can appoint up to nine ACCV voting members, evenly split among health professionals, attorneys and the general public — at least two of whom have children who were injured by a vaccine. Of the current roster, no member's term ends before July 2026, and it's unclear whether Kennedy might try to shake it up before then as he did with the CDC's independent vaccine panel. Drug Pricing LILLY'S MFN PLAY? Indianapolis-based Eli Lilly said Thursday it would raise prices on its drugs in European markets as a way to lower costs for American consumers — an apparent response to President Donald Trump's most-favored-nation pressure campaign, Lauren writes. The statement came two weeks after Trump sent letters to the leaders of major drug manufacturers — and posted them on social media — demanding they embrace most-favored-nation pricing that ties U.S. prices to lower figures paid in other wealthy nations or face unknown consequences. 'Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries,' the company said in a statement. When asked to elaborate on how the drugmaker will achieve that goal — and which drugs may be implicated — a company spokesperson referred to the online statement. Eye on the FDA GOLD STANDARD SCIENCE? The FDA quietly posted a new staff manual laying out the 'core tenets of gold standard science' online this week, following up on an executive order from President Donald Trump in May. 'In conducting our mission to protect and promote public health, FDA must generate and evaluate science in a manner that ensures FDA will make sound, objective decisions,' the staff manual states. 'Preserving and promoting GSS is essential to ensuring that FDA's mission succeeds and our regulatory decisions advance public health.' The document says the FDA will focus on reproducibility and replicable science, transparency in its research process, communication of errors and uncertainty and encouragement of collaborative and interdisciplinary approaches in science. It also says the FDA will embrace 'a culture of constructive skepticism in science through policies and programs that emphasize critical evaluation, transparency and objectivity,' values science that includes testable hypotheses with 'explicitly defined measurable criteria for falsification,' and recognizes the value of studies that have negative results. Document Drawer FDA Commissioner Marty Makary met with Sen. Steve Daines (R-Mont.) on July 30 to discuss abortion pill mifepristone, according to newly posted public calendar disclosures. He also held an introductory meeting with Sen. Amy Klobuchar (D-Minn.) on July 31. The FDA will hold a public meeting on Sept. 19 to discuss how to advance the development of interchangeable biosimilar products. The Health Resources and Services Administration is asking for feedback on its recommendation to add Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Uniform Screening Panel — a step that would require most insurers to cover the screenings without cost-sharing. WHAT WE'RE READING Costco will not dispense abortion pill mifepristone at its pharmacies, Bloomberg's Jeff Green and Jessica Nix report. President Donald Trump signed an executive order Wednesday directing HHS to stock drug ingredients to help bolster domestic supply, Lauren reports.

Yahoo
3 hours ago
- Yahoo
UK patients rush for obesity jab before Eli Lilly raises price 170% to appease Donald Trump
Patients are racing to secure the weight loss drug Mounjaro ahead of a price rise of up to 170 per cent in the UK, as drugmaker Eli Lilly
Yahoo
5 hours ago
- Yahoo
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data